

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILED WITH THE USPTO 9/25/07

Sheet 1 of 2

## Complete if Known

Application No.	10/773,356
Filing Date	February 5, 2004
First Named Inventor	Leslie P. Weiner
Art Unit	1644
Examiner Name	Gerald R. Ewoldt
Attorney Docket Number	23714-07992/US

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document No.	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number – Kind Code <sup>2</sup> (if known)		
		US-2003/0091578 A1	05-15-2003	Zhang

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T <sup>3</sup>
		Country Code <sup>3</sup> – Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
	B1	EP1015025 B1	12-15-2004	UNIVERSITY OF SOUTHERN CALIFORNIA	

## OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>5</sup>
	B2	"Expanded Disability Status Scale- Multiple Sclerosis Encyclopedia," last modified November 27, 2002, [online] [Retrieved on September 14, 2005] Retrieved from the Internet<URL:http://www.multiple-sclerosis.org/expandeddisabilitystatusscale.html>	
	B3	"PharmaFrontiers Presents Positive Tovaxin (TM) Research at International Multiple Sclerosis Meeting," Business Wire Information, October 3, 2005, 4 pages.	
	B4	BEN-NUN, A. et al., "Vaccination Against Autoimmune Encephalomyelitis with T-Lymphocyte Line Cells Reactive Against Myelin Basic Protein," Macmillan Journal, 1981, 2 pages.	
	B5	CONFAVREUX, C. et al., "Relapses and Progression of Disability in Multiple Sclerosis," The New England Journal of Medicine, November 16, 2000, pp. 1430-1438, Vol. 343, No. 20.	
	B6	CORREALE, J. et al., "Isolation and Characterization of Autoreactive Proteolipid Protein-Peptide Specific T-Cell Clones from Multiple Sclerosis Patients," Neurology, July 1995, pp. 1370-1378.	
	B7	CORREALE, J. et al., "Isolation and Characterization of CD8+ T Cell Clones (TCCs) that recognize autologous activated CD4+ TCCs from Chronic Progressive Multiple Sclerosis (MS) Patients: Implications for Immunoregulation in MS." Neurology, February 1996 S25.006, A280.	
	B8	JONES, P., "T Cell Vaccination Fails in Trial," All About Multiple Sclerosis, March 4, 2004, 1 page.	
	B9	KACHUCK, N., "T-Cell Immunization," May 2000, [online] [Retrieved on June 7, 2007] Retrieved from the Internet<URL:http://www.multiple-sclerosis.org/news/May2000/Tcellimmunization.html>	
	B10	KERLERO DE ROSBO, N.K. et al., "Reactivity to Myelin Antigens in Multiple Sclerosis," J. Clin. Invest., December 1993, pp. 2602-2608, Vol. 92.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

FILED WITH THE USPTO 9/25/07

Sheet 2 of 2

## Complete if Known

Application No.	10/773,356
Filing Date	February 5, 2004
First Named Inventor	Leslie P. Weiner
Art Unit	1644
Examiner Name	Gerald R. Ewoldt
Attorney Docket Number	23714-07992/US

## OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	B11	KRAWS and Goldfarb, "Personalized Cellular Therapeutic Opportunity," Executive Information Overview prepared by Crystal Research Associates for PharmaFrontiers Corp., November 21, 2005, pp. 1, 15-31.	
	B12	NEWSOM B.S. et al., "T Cell vaccination for MS characterization and clinical response" Abstract No. 131, Cytotherapy, ISCT 2006 Annual meeting Abstracts, 2006, Vol. 8, Suppl. 1.	
	B13	WARREN, K.G. et al., "Anti-Myelin Basic Protein and Anti-Proteolipid Protein Specific Forms of Multiple Sclerosis," Annals of Neurology, March 1994, pp. 280-289, Vol. 35, No. 3.	
	B14	WARREN, K.G. et al., "Purification of Primary Antibodies of the Myelin Basic Protein Antibody Cascade from Multiple Sclerosis Patients. Immunoreactivity Studies with Homologous and Heterologous Antigens," Clin. Invest. Med., 1992, pp. 18-29, Vol. 15, No. 1.	
	B15	WEINSHENKER, B.G. et al., "The Natural History of Multiple Sclerosis: A Geographically Based Study," Brain, 1989, pp. 133-146, Vol. 112.	
	B16	EP Application No. 98949378.8, Communication Pursuant to Article 96(2), April 14, 2003, 11 pages.	
	B17	PCT International Search Report, PCT/US98/19572, January 28, 1999, 4 pages.	
	B18	European Patent No. 1015025 Opposition Proceedings, Filing of a New Opposition, March 15, 2005, 2 pages.	
	B19	European Patent No. 1015025 Opposition Proceedings, Notice of Opposition, September 14, 2005, 16 pages.	
	B20	European Patent No. 1015025 Opposition Proceedings, Reply of the Patent Proprietor to the Notice(s) of Opposition, April 28, 2006, 2 pages.	
	B21	European Patent No. 1015025 Opposition Proceedings, Summons to Attend Oral Proceedings Pursuant to Rule 71(1) EPC and Annex to the Communication – Opposition, February 19, 2007, 7 pages.	
	B22	European Patent No. 1015025 Opposition Proceedings, Letter from the Opponent Regarding the Opposition Procedure (No Time Limit), June 7, 2007, 8 pages.	
	B23	European Patent No. 1015025 Opposition Proceedings, Letter from the Proprietor Regarding the Opposition Procedure (No Time Limit), June 8, 2007, 10 pages.	
	B24	European Patent No. 1015025 Opposition Proceedings, Letter from the Proprietor Regarding the Opposition Procedure (No Time Limit), June 26, 2007, 71 pages.	
	B25	European Patent No. 1015025 Opposition Proceedings, Letter from the Opponent Regarding the Opposition Procedure, July 3, 2007, 16 pages.	
	B26	European Patent No. 1015025 Opposition Proceedings, Information about the result of Oral proceedings, July 12, 2007, 1 pages	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.